{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:54:14Z","timestamp":1788328454029,"version":"build-2803163510"},"reference-count":15,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T00:00:00Z","timestamp":1685232000000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000735","name":"University of Cambridge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Influenza Resp Viruses"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There are concerns that sotrovimab has reduced efficacy at reducing hospitalisation risk against the BA.2 sub\u2010lineage of the Omicron SARS\u2010CoV\u20102 variant. We performed a retrospective cohort (n\u2009=\u20098850) study of individuals treated with sotrovimab in the community, with the objective of assessing whether there were any differences in risk of hospitalisation of BA.2 cases compared with BA.1. We estimated that the hazard ratio of hospital admission with a length of stay of 2\u2009days or more was 1.17 for BA.2 compared with BA.1 (95%CI 0.74\u20131.86). These results suggest that the risk of hospital admission was similar between the two sub\u2010lineages.<\/jats:p>","DOI":"10.1111\/irv.13150","type":"journal-article","created":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T22:10:05Z","timestamp":1685311805000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID\u201019 cases treated with sotrovimab in the community in England"],"prefix":"10.1111","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1387-0200","authenticated-orcid":false,"given":"Katie","family":"Harman","sequence":"first","affiliation":[{"name":"UKHSA COVID\u201019 National Epidemiology Cell  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7717-6982","authenticated-orcid":false,"given":"Sophie Grace","family":"Nash","sequence":"additional","affiliation":[{"name":"UKHSA COVID\u201019 National Epidemiology Cell  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-8884","authenticated-orcid":false,"given":"Harriet H.","family":"Webster","sequence":"additional","affiliation":[{"name":"UKHSA COVID\u201019 National Epidemiology Cell  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3832-3484","authenticated-orcid":false,"given":"Natalie","family":"Groves","sequence":"additional","affiliation":[{"name":"UKHSA Genomics and Public Health Analysis  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3345-209X","authenticated-orcid":false,"given":"Jo","family":"Hardstaff","sequence":"additional","affiliation":[{"name":"UKHSA Outbreak Surveillance Team  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5497-2700","authenticated-orcid":false,"given":"Jessica","family":"Bridgen","sequence":"additional","affiliation":[{"name":"UKHSA Outbreak Surveillance Team  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3962-4211","authenticated-orcid":false,"given":"Paula B.","family":"Blomquist","sequence":"additional","affiliation":[{"name":"UKHSA Outbreak Surveillance Team  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2838-6833","authenticated-orcid":false,"given":"Russell","family":"Hope","sequence":"additional","affiliation":[{"name":"UKHSA COVID\u201019 National Epidemiology Cell  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4746-282X","authenticated-orcid":false,"given":"Efejiro","family":"Ashano","sequence":"additional","affiliation":[{"name":"UKHSA HCAI, Fungal, AMR, AMU &amp; Sepsis Division  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4269-1164","authenticated-orcid":false,"given":"Richard","family":"Myers","sequence":"additional","affiliation":[{"name":"UKHSA Genomics and Public Health Analysis  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2955-4907","authenticated-orcid":false,"given":"Sakib","family":"Rokadiya","sequence":"additional","affiliation":[{"name":"UKHSA COVID\u201019 Therapeutics  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5179-5702","authenticated-orcid":false,"given":"Susan","family":"Hopkins","sequence":"additional","affiliation":[{"name":"UKHSA Chief Medical Advisor  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4776-3403","authenticated-orcid":false,"given":"Colin S.","family":"Brown","sequence":"additional","affiliation":[{"name":"UKHSA HCAI, Fungal, AMR, AMU &amp; Sepsis Division &amp; NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-0340","authenticated-orcid":false,"given":"Meera","family":"Chand","sequence":"additional","affiliation":[{"name":"UKHSA Genomics and Public Health Analysis  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4606-5945","authenticated-orcid":false,"given":"Gavin","family":"Dabrera","sequence":"additional","affiliation":[{"name":"UKHSA COVID\u201019 National Epidemiology Cell  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0434-2724","authenticated-orcid":false,"given":"Simon","family":"Thelwall","sequence":"additional","affiliation":[{"name":"UKHSA COVID\u201019 National Epidemiology Cell  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,28]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"National Institute for Health and Care Excellence BNF.Sotrovimab.https:\/\/bnf.nice.org.uk\/drug\/sotrovimab.html#indicationsAndDoses. Accessed 9 May 2022."},{"key":"e_1_2_10_3_1","unstructured":"Medicines and Healthcare products Regulatory Agency.Regulatory approval of Xevudy (sotrovimab).https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-xevudy-sotrovimab. Accessed 9 May 2022."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.04.010"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107934"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2201933"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","unstructured":"ZhouH TadaT DcostaBM LandauNR.Neutralization of SARS\u2010CoV\u20102 Omicron BA.2 by therapeutic monoclonal antibodies. Preprint. bioRxiv. 2022;2022.02.15.480166.2022.10.1101\/2022.02.15.480166.","DOI":"10.1101\/2022.02.15.480166"},{"key":"e_1_2_10_8_1","unstructured":"U.S. Food & Drug Administration.FDA updates sotrovimab emergency use authorization 2022.https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-sotrovimab-emergency-use-authorization. Accessed 9 May 2022."},{"key":"e_1_2_10_9_1","unstructured":"Department of Health and Social Care The Scottish Government Welsh Government Department of Health NHS.Interim Clinical Commissioning Policy: antivirals or neutralising monoclonal antibodies in the treatment of hospital\u2010onset COVID\u201019 (Version 6) 2022.https:\/\/www.england.nhs.uk\/coronavirus\/publication\/interim-clinical-commissioning-policy-antivirals-or-neutralising-monoclonal-antibodies-in-the-treatment-of-hospital-onset-covid-19\/. Accessed 13 May 2022."},{"key":"e_1_2_10_10_1","unstructured":"NHS England.COVID\u201019 Therapeutics (antivirals neutralising monoclonal antibodies and interleukin 6 inhibitors) 2022 [13\/05\/2022].https:\/\/www.england.nhs.uk\/statistics\/statistical-work-areas\/covid-therapeutics-antivirals-and-neutralising-monoclonal-antibodies\/. Accessed 13 May 2022."},{"key":"e_1_2_10_11_1","unstructured":"UK Health Security Agency.COVID\u201019 therapeutic agents: technical briefing 3 2022 [16\/05\/2022].https:\/\/www.gov.uk\/government\/publications\/covid-19-therapeutic-agents-technical-briefings. Accessed 16 May 2022."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2021.03.012"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010022\u201033740\u20109"},{"key":"e_1_2_10_14_1","unstructured":"UK Health Security Agency.UK Health Security Agency (UKHSA). SARS\u2010CoV\u20102 variants of concern and variants under investigation in England.https:\/\/www.gov.uk\/government\/publications\/investigation-of-sars-cov-2-variants-technical-briefings. Technical briefing 36 London2022 Accessed 16 May 2022."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(22)00462\u20107"},{"key":"e_1_2_10_16_1","unstructured":"Cabinet Office.COVID\u201019 Response: Living with COVID\u201019 2022.https:\/\/www.gov.uk\/government\/publications\/covid-19-response-living-with-covid-19. Accessed 4 May 2022."}],"container-title":["Influenza and Other Respiratory Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/irv.13150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T15:45:31Z","timestamp":1692459931000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/irv.13150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/irv.13150"],"URL":"https:\/\/doi.org\/10.1111\/irv.13150","archive":["Portico"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.10.21.22281171","asserted-by":"object"}]},"ISSN":["1750-2640","1750-2659"],"issn-type":[{"value":"1750-2640","type":"print"},{"value":"1750-2659","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"2023-01-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13150"}}